“Glucagon-like peptide-1 agonist (GLP-1) drugs have transformed type 2 diabetes care, but weekly injections can be burdensome for patients. A single shot a month could make it much easier for people living with diabetes or obesity to stick to their drug regimens, improving quality of li...
Frid A, Hirsch L, Gaspar G, et al.: New injection recom- mendations for patients with diabetes. Diabetes Metab 2010; 36(Suppl 2):S3-S18.Davidson JA. New injection recommendations for patients with diabetes. Diabetes Metab 2010;36 Suppl 2:S2....
On the other hand, in 2023, FDA approved a groundbreaking therapy for the treatment of type 1 diabetes.Donislecel-jujnis the first allogeneic pancreatic islet cellular therapy obtained from deceased donors’ pancreatic cells, designed to address the challenges faced by diabetic patients unable to co...
Medications for diabetes comprise either GLP-1 receptor agonists, with short (one or two daily injections: Exenatide, Liraglutide, Lixisenatide) or long duration (one injection once weekly: extended-released Exenatide, Albiglutide, Dulaglutide, Taspoglutide); or oral compounds inhibiting dipeptidyl peptid...
Reduce risk of Flu, Cancer, Heart Disease, Depression, Diabetes, Osteoporosis and so much more. read more NAD+ Injection Improves cardiovascular health, boosts energy, increases metabolism and reduces inflammation. read more Vitamin C Injection Improves skin elasticity and it lightens the skin...
a diabetes drug useful for both types 1 and 2, and Merck made $1.3 billion off its Januvia franchise in the first quarter of this year alone. So hopes are pinned on Pfizer’s tofacitinib, currently under FDA review, as the treatment with the potential to earn $1 billion or more in sal...
The Food and Drug Administration (FDA) has approved a novel first-in-class drug to treat type 2 diabetes. The drug is called tirzepatide. A person has it as a once-weekly injection under the skin. It has a dual effect, lowering blood sugar and supporting weight loss better than currentl...
independently developed glucagon-like peptide-1 (GLP-1) receptor agonist, GZR18 Injection, in an obese/overweight population in China, along with the results of two other innovative insulins' preclinical studies in poster presentations at the American Diabetes Association's(ADA's)84th Scientific ...
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–39. Article CAS PubMed PubMed Central Google Scholar Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes ...
“incredibly dangerous”. Studies show that losing and regaining weight could increase the risk of conditions such as diabetes. “All of the things we attribute to fatness, like cardiovascular risk, diabetes, depression, anxiety . . . have actually been found to be related to weight ...